Aragon Pharmaceuticals, Inc.

This study tested whether adding apalutamide to standard hormone therapy helps men with prostate cancer that has spread. Over 1,000 participants received either the combination or hormone therapy alone. The goal was to see if the combination delays cancer growth and improves surv…

This study provides early access to apalutamide for men with a type of prostate cancer that has stopped responding to hormone therapy but has not yet spread. The goal is to gather more safety information while offering the drug before it becomes widely available. Participants mus…

This study tests whether adding the drug apalutamide to standard hormone therapy and radiation can delay the spread of prostate cancer in people with high-risk, localized disease. About 1,500 participants will receive either the drug combination or a placebo. The main goal is to …

This study tested whether adding the drug apalutamide to a standard two-drug therapy (abiraterone and prednisone) could help men with a certain type of advanced prostate cancer that had stopped responding to hormone therapy but had not yet received chemotherapy. About 982 men too…

This study looked at how two prostate cancer drugs (JNJ-56021927 and abiraterone acetate) interact in the body and whether combining them is safe. It involved 57 men with metastatic castration-resistant prostate cancer, a type that no longer responds to standard hormone therapy. …

This study tested a drug called apalutamide in over 1,200 men with a type of prostate cancer that has stopped responding to hormone therapy but has not yet spread. The goal was to see if the drug could delay the cancer from spreading to bones or other organs. Participants receive…

This study looks at how a drug called JNJ-56021927 affects the way the body processes other common medications in men with castration-resistant prostate cancer. 23 participants will take the study drug along with several other drugs to measure changes in drug levels. The goal is …